Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
RydaptⓇ - Multi-targeted kinase inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03591510 (CPKC412A2218)
Acute myeloid leukemia, pediatrics
Phase 2
20
Occurrence of dose limiting toxicities
Safety and Tolerability
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia
(AML)
Target Patients
Read-out Milestone(s)
2026
Publication
TBD
133 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation